The European Prevention of Alzheimer’s Disease (Euro-PAD) community seeks to enhance and extend late-stage biomarker cohorts focused on Alzheimer’s dementia, with the specific aim of establishing the most extensive and deeply phenotyped longitudinal cohort of at-risk individuals. By focusing on preclinical and prodromal stages of Alzheimer’s disease (AD), Euro-PAD aims to unlock critical insights into the earliest stages of AD.

Leveraging on the collaborative framework established within the AMYPAD consortium through the Prognostic and Natural History Study (PNHS), Euro-PAD is expanding its network to collect, harmonise, and integrate data from multiple European cohorts. With existing collaborators in Netherlands, Germany, Belgium, France, Spain, Sweden, Switzerland, and UK, the Euro-PAD community brings together experts across key aspects in the neurodegenerative field. 

We will continue our commitment to open science, by making novel-derived data openly available as soon as possible through our ongoing collaboration with the Alzheimer’s Disease Data Initiative (ADDI). The valuable data generated by the EPAD-LCS and AMYPAD-PNHS is already available to the research community through the AD Workbench platform.

The EuroPAD initiative aims to integrate the wealth of existing data in Europe, to enable advanced multi-modal disease modelling and answer key clinical questions.

Eligible cohorts include:

• Participants without dementia at baseline (i.e., CDR=0 or CDR=0.5)
• Participants have available data in at least 1 core Euro-PAD variable:
    - Cognitive data across all the domains (attention, executive function, verbal function, episodic memory, and visuospatial function)
    - MR imaging;
    - AD biomarker (plasma, CSF, PET).

Are you interested in joining the Euro-PAD community? Please contact e.s.luckett@amsterdamumc.nl or l.collij@amsterdamumc.nl.